Immunogenicity after pre- and post-exposure rabies vaccination: A systematic review and dose-response meta-analysis
There are a myriad of vaccine schedules for rabies pre- (PrEP) and post-exposure prophylaxis (PEP) that differ in the number and timedoses, number of visits, length of schedule, and route of administration. The objective of this study was to systematically review the evidence and investigate how the...
Gespeichert in:
| Veröffentlicht in: | Vaccine 2021-02, Vol.39 (7), p.1044-1050 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1050 |
|---|---|
| container_issue | 7 |
| container_start_page | 1044 |
| container_title | Vaccine |
| container_volume | 39 |
| creator | Xu, Chang Lau, Colleen L. Clark, Justin Rafferty, Anna C. Mills, Deborah J. Ramsey, Lani Gilbert, Brian Doi, Suhail A.R. Furuya-Kanamori, Luis |
| description | There are a myriad of vaccine schedules for rabies pre- (PrEP) and post-exposure prophylaxis (PEP) that differ in the number and timedoses, number of visits, length of schedule, and route of administration. The objective of this study was to systematically review the evidence and investigate how thedifferences in schedules influence titres over time.
Four databaseswere searched from inception to January 2020 for rabies PrEP and PEP studies. Adose–response meta-analysis was utilised to pool geometric mean titres (GMT) over time. Subgroup analyses by route of administration, age group, and schedule were conducted.
80 studies met the inclusion criteria and contributed with 191 datasets and 12,413 participants. Both intradermal (ID) and intramuscular (IM) PrEP/PEP produce adequate GMTs. Significantly lower GMT levels were achieved in older (>50yrs) compared to younger ( |
| doi_str_mv | 10.1016/j.vaccine.2021.01.023 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2480406856</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0264410X21000396</els_id><sourcerecordid>2485503828</sourcerecordid><originalsourceid>FETCH-LOGICAL-c393t-35bfac4357e5b4a9a3dae238f666e501567dc9a29482c202ad70eb846f1f64593</originalsourceid><addsrcrecordid>eNqFkU9rFEEQxRtRzCb6EZQGL1567f_T40VC0BgIeFHw1vT01EgvO9Nj10zifns72dWDF6GgKPi9quI9Ql4JvhVc2He77V2IMU2wlVyKLa8l1ROyEa5RTBrhnpINl1YzLfj3M3KOuOOcGyXa5-RMKd24xtkNwZtxXKf8A6YU03KgYVig0LkAo2Hq6ZxxYfCrtrUALaFLgPR4OCwpT-_pJcUDLjDWMdICdwnuH5V9RmAFcM4TAh1hCSxMYX_AhC_IsyHsEV6e-gX59unj16vP7PbL9c3V5S2LqlULU6YbQtTKNGA6Hdqg-gBSucFaC4YLY5s-tkG22slYTQh9w6Fz2g5isNq06oK8Pe6dS_65Ai5-TBhhvw8T5BW91I5rbp2xFX3zD7rLa6n_PlLGcOWkq5Q5UrFkxAKDn0saQzl4wf1DKn7nT6n4h1Q8ryVV1b0-bV-7Efq_qj8xVODDEYBqR7WweIwJpgh9KhAX3-f0nxO_AYOboZg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2485503828</pqid></control><display><type>article</type><title>Immunogenicity after pre- and post-exposure rabies vaccination: A systematic review and dose-response meta-analysis</title><source>Elsevier ScienceDirect Journals Complete</source><source>ProQuest Central UK/Ireland</source><creator>Xu, Chang ; Lau, Colleen L. ; Clark, Justin ; Rafferty, Anna C. ; Mills, Deborah J. ; Ramsey, Lani ; Gilbert, Brian ; Doi, Suhail A.R. ; Furuya-Kanamori, Luis</creator><creatorcontrib>Xu, Chang ; Lau, Colleen L. ; Clark, Justin ; Rafferty, Anna C. ; Mills, Deborah J. ; Ramsey, Lani ; Gilbert, Brian ; Doi, Suhail A.R. ; Furuya-Kanamori, Luis</creatorcontrib><description>There are a myriad of vaccine schedules for rabies pre- (PrEP) and post-exposure prophylaxis (PEP) that differ in the number and timedoses, number of visits, length of schedule, and route of administration. The objective of this study was to systematically review the evidence and investigate how thedifferences in schedules influence titres over time.
Four databaseswere searched from inception to January 2020 for rabies PrEP and PEP studies. Adose–response meta-analysis was utilised to pool geometric mean titres (GMT) over time. Subgroup analyses by route of administration, age group, and schedule were conducted.
80 studies met the inclusion criteria and contributed with 191 datasets and 12,413 participants. Both intradermal (ID) and intramuscular (IM) PrEP/PEP produce adequate GMTs. Significantly lower GMT levels were achieved in older (>50yrs) compared to younger (<50yrs) participants. Short 1-week schedules were as effective as longer schedules that can take between 3 and 12 weeks to complete.
Several effective ID and IM schedules were identified, the selection of a schedule should take into account the patient’s needs, costs, availability to return for subsequent doses, and the time required to complete the schedule. Older individuals warrant special attention as they develop lower antibody response.</description><identifier>ISSN: 0264-410X</identifier><identifier>EISSN: 1873-2518</identifier><identifier>DOI: 10.1016/j.vaccine.2021.01.023</identifier><identifier>PMID: 33478786</identifier><language>eng</language><publisher>Netherlands: Elsevier Ltd</publisher><subject>Antibodies ; Antibody response ; Immunogenicity ; Immunoglobulins ; Intradermal ; Intramuscular ; Medical research ; Meta-analysis ; Prophylaxis ; Rabies ; Schedules ; Seroconversion ; Seropositive ; Subgroups ; Systematic review ; Titre ; Vaccination ; Vaccine ; Vaccines</subject><ispartof>Vaccine, 2021-02, Vol.39 (7), p.1044-1050</ispartof><rights>2021 Elsevier Ltd</rights><rights>Copyright © 2021 Elsevier Ltd. All rights reserved.</rights><rights>2021. Elsevier Ltd</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c393t-35bfac4357e5b4a9a3dae238f666e501567dc9a29482c202ad70eb846f1f64593</citedby><cites>FETCH-LOGICAL-c393t-35bfac4357e5b4a9a3dae238f666e501567dc9a29482c202ad70eb846f1f64593</cites><orcidid>0000-0002-2627-1250 ; 0000-0001-7433-0430 ; 0000-0003-2934-9524 ; 0000-0003-0133-1613</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.proquest.com/docview/2485503828?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995,64385,64387,64389,72469</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33478786$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Xu, Chang</creatorcontrib><creatorcontrib>Lau, Colleen L.</creatorcontrib><creatorcontrib>Clark, Justin</creatorcontrib><creatorcontrib>Rafferty, Anna C.</creatorcontrib><creatorcontrib>Mills, Deborah J.</creatorcontrib><creatorcontrib>Ramsey, Lani</creatorcontrib><creatorcontrib>Gilbert, Brian</creatorcontrib><creatorcontrib>Doi, Suhail A.R.</creatorcontrib><creatorcontrib>Furuya-Kanamori, Luis</creatorcontrib><title>Immunogenicity after pre- and post-exposure rabies vaccination: A systematic review and dose-response meta-analysis</title><title>Vaccine</title><addtitle>Vaccine</addtitle><description>There are a myriad of vaccine schedules for rabies pre- (PrEP) and post-exposure prophylaxis (PEP) that differ in the number and timedoses, number of visits, length of schedule, and route of administration. The objective of this study was to systematically review the evidence and investigate how thedifferences in schedules influence titres over time.
Four databaseswere searched from inception to January 2020 for rabies PrEP and PEP studies. Adose–response meta-analysis was utilised to pool geometric mean titres (GMT) over time. Subgroup analyses by route of administration, age group, and schedule were conducted.
80 studies met the inclusion criteria and contributed with 191 datasets and 12,413 participants. Both intradermal (ID) and intramuscular (IM) PrEP/PEP produce adequate GMTs. Significantly lower GMT levels were achieved in older (>50yrs) compared to younger (<50yrs) participants. Short 1-week schedules were as effective as longer schedules that can take between 3 and 12 weeks to complete.
Several effective ID and IM schedules were identified, the selection of a schedule should take into account the patient’s needs, costs, availability to return for subsequent doses, and the time required to complete the schedule. Older individuals warrant special attention as they develop lower antibody response.</description><subject>Antibodies</subject><subject>Antibody response</subject><subject>Immunogenicity</subject><subject>Immunoglobulins</subject><subject>Intradermal</subject><subject>Intramuscular</subject><subject>Medical research</subject><subject>Meta-analysis</subject><subject>Prophylaxis</subject><subject>Rabies</subject><subject>Schedules</subject><subject>Seroconversion</subject><subject>Seropositive</subject><subject>Subgroups</subject><subject>Systematic review</subject><subject>Titre</subject><subject>Vaccination</subject><subject>Vaccine</subject><subject>Vaccines</subject><issn>0264-410X</issn><issn>1873-2518</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqFkU9rFEEQxRtRzCb6EZQGL1567f_T40VC0BgIeFHw1vT01EgvO9Nj10zifns72dWDF6GgKPi9quI9Ql4JvhVc2He77V2IMU2wlVyKLa8l1ROyEa5RTBrhnpINl1YzLfj3M3KOuOOcGyXa5-RMKd24xtkNwZtxXKf8A6YU03KgYVig0LkAo2Hq6ZxxYfCrtrUALaFLgPR4OCwpT-_pJcUDLjDWMdICdwnuH5V9RmAFcM4TAh1hCSxMYX_AhC_IsyHsEV6e-gX59unj16vP7PbL9c3V5S2LqlULU6YbQtTKNGA6Hdqg-gBSucFaC4YLY5s-tkG22slYTQh9w6Fz2g5isNq06oK8Pe6dS_65Ai5-TBhhvw8T5BW91I5rbp2xFX3zD7rLa6n_PlLGcOWkq5Q5UrFkxAKDn0saQzl4wf1DKn7nT6n4h1Q8ryVV1b0-bV-7Efq_qj8xVODDEYBqR7WweIwJpgh9KhAX3-f0nxO_AYOboZg</recordid><startdate>20210212</startdate><enddate>20210212</enddate><creator>Xu, Chang</creator><creator>Lau, Colleen L.</creator><creator>Clark, Justin</creator><creator>Rafferty, Anna C.</creator><creator>Mills, Deborah J.</creator><creator>Ramsey, Lani</creator><creator>Gilbert, Brian</creator><creator>Doi, Suhail A.R.</creator><creator>Furuya-Kanamori, Luis</creator><general>Elsevier Ltd</general><general>Elsevier Limited</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QL</scope><scope>7RV</scope><scope>7T2</scope><scope>7T5</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88C</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0R</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>M2O</scope><scope>M7N</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-2627-1250</orcidid><orcidid>https://orcid.org/0000-0001-7433-0430</orcidid><orcidid>https://orcid.org/0000-0003-2934-9524</orcidid><orcidid>https://orcid.org/0000-0003-0133-1613</orcidid></search><sort><creationdate>20210212</creationdate><title>Immunogenicity after pre- and post-exposure rabies vaccination: A systematic review and dose-response meta-analysis</title><author>Xu, Chang ; Lau, Colleen L. ; Clark, Justin ; Rafferty, Anna C. ; Mills, Deborah J. ; Ramsey, Lani ; Gilbert, Brian ; Doi, Suhail A.R. ; Furuya-Kanamori, Luis</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c393t-35bfac4357e5b4a9a3dae238f666e501567dc9a29482c202ad70eb846f1f64593</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Antibodies</topic><topic>Antibody response</topic><topic>Immunogenicity</topic><topic>Immunoglobulins</topic><topic>Intradermal</topic><topic>Intramuscular</topic><topic>Medical research</topic><topic>Meta-analysis</topic><topic>Prophylaxis</topic><topic>Rabies</topic><topic>Schedules</topic><topic>Seroconversion</topic><topic>Seropositive</topic><topic>Subgroups</topic><topic>Systematic review</topic><topic>Titre</topic><topic>Vaccination</topic><topic>Vaccine</topic><topic>Vaccines</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Xu, Chang</creatorcontrib><creatorcontrib>Lau, Colleen L.</creatorcontrib><creatorcontrib>Clark, Justin</creatorcontrib><creatorcontrib>Rafferty, Anna C.</creatorcontrib><creatorcontrib>Mills, Deborah J.</creatorcontrib><creatorcontrib>Ramsey, Lani</creatorcontrib><creatorcontrib>Gilbert, Brian</creatorcontrib><creatorcontrib>Doi, Suhail A.R.</creatorcontrib><creatorcontrib>Furuya-Kanamori, Luis</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Nursing & Allied Health Database</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Vaccine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Xu, Chang</au><au>Lau, Colleen L.</au><au>Clark, Justin</au><au>Rafferty, Anna C.</au><au>Mills, Deborah J.</au><au>Ramsey, Lani</au><au>Gilbert, Brian</au><au>Doi, Suhail A.R.</au><au>Furuya-Kanamori, Luis</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Immunogenicity after pre- and post-exposure rabies vaccination: A systematic review and dose-response meta-analysis</atitle><jtitle>Vaccine</jtitle><addtitle>Vaccine</addtitle><date>2021-02-12</date><risdate>2021</risdate><volume>39</volume><issue>7</issue><spage>1044</spage><epage>1050</epage><pages>1044-1050</pages><issn>0264-410X</issn><eissn>1873-2518</eissn><abstract>There are a myriad of vaccine schedules for rabies pre- (PrEP) and post-exposure prophylaxis (PEP) that differ in the number and timedoses, number of visits, length of schedule, and route of administration. The objective of this study was to systematically review the evidence and investigate how thedifferences in schedules influence titres over time.
Four databaseswere searched from inception to January 2020 for rabies PrEP and PEP studies. Adose–response meta-analysis was utilised to pool geometric mean titres (GMT) over time. Subgroup analyses by route of administration, age group, and schedule were conducted.
80 studies met the inclusion criteria and contributed with 191 datasets and 12,413 participants. Both intradermal (ID) and intramuscular (IM) PrEP/PEP produce adequate GMTs. Significantly lower GMT levels were achieved in older (>50yrs) compared to younger (<50yrs) participants. Short 1-week schedules were as effective as longer schedules that can take between 3 and 12 weeks to complete.
Several effective ID and IM schedules were identified, the selection of a schedule should take into account the patient’s needs, costs, availability to return for subsequent doses, and the time required to complete the schedule. Older individuals warrant special attention as they develop lower antibody response.</abstract><cop>Netherlands</cop><pub>Elsevier Ltd</pub><pmid>33478786</pmid><doi>10.1016/j.vaccine.2021.01.023</doi><tpages>7</tpages><orcidid>https://orcid.org/0000-0002-2627-1250</orcidid><orcidid>https://orcid.org/0000-0001-7433-0430</orcidid><orcidid>https://orcid.org/0000-0003-2934-9524</orcidid><orcidid>https://orcid.org/0000-0003-0133-1613</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0264-410X |
| ispartof | Vaccine, 2021-02, Vol.39 (7), p.1044-1050 |
| issn | 0264-410X 1873-2518 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2480406856 |
| source | Elsevier ScienceDirect Journals Complete; ProQuest Central UK/Ireland |
| subjects | Antibodies Antibody response Immunogenicity Immunoglobulins Intradermal Intramuscular Medical research Meta-analysis Prophylaxis Rabies Schedules Seroconversion Seropositive Subgroups Systematic review Titre Vaccination Vaccine Vaccines |
| title | Immunogenicity after pre- and post-exposure rabies vaccination: A systematic review and dose-response meta-analysis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T10%3A26%3A05IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Immunogenicity%20after%20pre-%20and%20post-exposure%20rabies%20vaccination:%20A%20systematic%20review%20and%20dose-response%20meta-analysis&rft.jtitle=Vaccine&rft.au=Xu,%20Chang&rft.date=2021-02-12&rft.volume=39&rft.issue=7&rft.spage=1044&rft.epage=1050&rft.pages=1044-1050&rft.issn=0264-410X&rft.eissn=1873-2518&rft_id=info:doi/10.1016/j.vaccine.2021.01.023&rft_dat=%3Cproquest_cross%3E2485503828%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2485503828&rft_id=info:pmid/33478786&rft_els_id=S0264410X21000396&rfr_iscdi=true |